AstraZeneca vaccine: Guillain-Barre syndrome a side effect EMA – Are you at Risk?

The European Medicines Agency has listed Guillain Barre syndrome as a side effect to the AstraZeneca covid vaccine. This condition affects nerves and is serious. Most of the symptoms are felt in the feet, hands, and limbs. Temporary paralysis may occur in some instances.

However, the side effects have been called “very rare.”

According to the EMA, the relationship is “considered at most a reasonable possibility” after 833 cases were reported in the world by Wednesday. This was after around 592,000,000 doses of AstraZeneca vaccinations had been administered.

It stated that GBS should be included in the product information because it is a side effect Vaxzevria.

The EMA suggested that a warning about the vaccine be included. It warns that people should seek treatment if they experience weakness or paralysis in their extremities. This could lead to infections that reach the chest or face.

LEARN MOREParkinson’s symptoms: You shouldn’t overlook the smelly signs of Parkinson’s disease

Guillain Barre Syndrome was previously recognized by the European Drug Regulatory Agency as a side effect of Johnson & Johnson’s vaccine. It uses the same adenovirus technology that AstraZeneca.

In July, the US Food and Drug Administration warned of an increased risk of getting this condition from Johnson & Johnson’s jab.

Both regulators stressed that the vaccine had many benefits and was worth the risks.

According to the UK Government, there would likely be a few cases of GBS after vaccinations since all UK adults have received the coronavirus (COVID-19 vaccine).


The article states that there were 383 GBS reports in the UK following AstraZeneca’s (AZ) vaccine and 23 Miller Fisher syndrome reports. Miller Fisher syndrome is a form of GBS that causes paralysis, abnormal muscle coordination and tendon reflex loss.

There were 42 cases of GBS after BioNTech/Pfizer vaccinations, and two following Moderna.

Over this period 24.8 Million first doses, 23.9 Miil second doses, of the AZ vaccine were administered. 21.0 MILLION first doses, 24.7 Second doses, of Pfizer/BioNTech vaccine were administered. 1.4M first doses, 0.6M second doses, of Moderna vaccine, have also been given.

All suspected GBS cases in the UK should be reported using the COVID-19 yellow card scheme to the MHRA.

Current advice states that anyone with GBS following their initial COVID-19 vaccination should get the second one.

GOV.UK says: “There are no indications that an individual is predisposed to receiving further episodes of GBS.”

The balance of benefit and risk is in favor of full COVID-19 vaccines for those with GBS after COVID-19.

It is not possible to prove a causal relationship between GBS and COVID-19 vaccines. GBS cases that do occur after vaccinations may be due to chance. The background GBS rate for GBS in the United States is 2 per 100,000.

The same vaccine should be used for the entire vaccination program. There are known side effects that can occur if you use multiple schedules.

Persons who have had GBS that is not related to COVID-19 should be vaccinated.

The report states that there has been no causal relationship between GBS and COVID-19 vaccine. There is also no evidence to suggest that GBS rates are higher in those who received COVID-19.

The balance of risks and benefits is in favor of full COVID-19 vaccine schedule.

Publited at Thu, 9 Sep 2021 12:09.10 +0000

Leave a Reply

Your email address will not be published. Required fields are marked *